Nightingale Health Plc provides advanced health check and remote health check products designed for the healthcare, insurance, government, and consumer health sectors. The company also offers proprietary 'omics technology and preventive screening solutions to support medical research and disease risk detection.
Subscribe to see Nightingale Health Plc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nightingale Health Plc is a biotech company headquartered in Helsinki, Finland. Xcout tracks 1 named person at Nightingale Health Plc, including Teemu Suna (CEO).
As of 16 November 2026. Source: Xcout Intel.
A few of Nightingale Health Plc's closest competitors — see the full list of competitors and alternatives →
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Genomics plc is an industry leader in identifying an individual's absolute risk of disease using a platform powered by a large genetic database.
Clear Health Pass Holdings LLC develops and provides advanced in-vitro diagnostic testing solutions, including saliva and fecal-based health diagnostic collections, genomics, and medical wellness testing. The company serves medical facilities, businesses, and government entities with diagnostic tools spanning areas such as cardiology, diabetes, genetics, women's health, allergies, and drug screening.
BGI Group provides genomic and precision medicine testing products, services, and solutions. The company serves the healthcare and clinical sectors by offering diagnostics and screening for reproductive health, oncology, infectious diseases, and chronic illnesses.
Inngenetics provides advanced genetic testing services, including whole-genome panels, oncology diagnostics, and hereditary disease screening.
IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Nightingale Health Plc? Suggest a correction · Work at Nightingale Health Plc? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.